Trametinib is a selective, allosteric MEK1/MEK2 inhibitor, also known as GSL1120212, which was recently investigated in a phase II clinical trial designed to determine the response rate for patients with metastatic BRAF mutant melanoma. This evidence concerns the gene BRAF and melanoma.